LUNAC Therapeutics (LUNAC) along with the Medicines Discovery Catapult and the University of Leeds, has been awarded £3.14M funding.
Strategic collaboration will enable preclinical assessment and inform clinical development strategy for Redx’s Porcupine (RXC006) and ROCK2 inhibitors for fibrotic diseases with high unmet medical need.
Cystic Fibrosis Syndicate in Antimicrobial Resistance launches
Driving innovation into state-of-the-art technologies such as Artificial Intelligence and Complex Cell Models is key to maintaining the UK’s global competitiveness.
The UK Government has announced a £55m five-year investment in Medicines Discovery Catapult.
Medicines Discovery Catapult and AstraZeneca collaborate to unlock the potential of Acoustic Mist Ionisation Mass Spectrometry.
OptibriumTM, Intellegens and Medicines Discovery Catapult awarded funding to apply machine learning in drug discovery.
Medicines Discovery Catapult has appointed Dr Robin Brown as its new Chairman.
CEO, Chris Molloy, discusses the role of Medicines Discovery Catapult within the UK as a centre for applied medical R&D.
Business Secretary Greg Clark launched the Rosalind Franklin Institute.
See how we can help support you with your next drug discovery project.
Speak to us